ASCO 2024

Immunotherapy makes a difference in survival in eTNBC

Prognostic value of ctDNA in therapeutic strategies; Endocrine therapy in ER-low BC

The search for predicitve biomarkers continues

Avelumab in early TNBC

Adjuvant endocrine therapy for ER-low EBC

AI for the prediction of disease progression

Personalized neoadjuvant therapy for high-risk breast cancer patients

Ribociclib is also effective in N0 HR+/HER2− EBC

ctDNA analysis in monarchE

Advantage for node-negative patients

ctDNA important for HR+ eBC?

Avelumab nel TNBC precoce

Reassuring and clarifying new data for CDK4/6 inhibitors

Expanding T-DxD use to HER2 ultra-low - the success story continues

One step closer to chemo-free therapy for HR+/HER2+ patients

Improvement for firstline treatment for patients with endocrine resistance

Responder premenopausal

Systemic therapy of HER2+ patients with brain metastases

Heterogenity of ER+ disease

Triple positive mBC - chemotherapy unnecessary?

Eribulin, Trastuzumab, Pertuzumab in 1stL HER2+ mBC

Is there still a place for endocrine therapy in HER2+ BC

ER-low: endocrine therapy necessary after all?

New data on the omission of chemotherapy in young patients

Leptomeningeal metastases in HER2+ mBC

Ultra low - ultra good?

Decreasing SG related toxicity with profilatic G-CFS

Broaden T-DXD as therapy standard for HER2low and ultra-low MBC

Important OS benefit with T-Dxd in HER2+ mBC

T-DXD continues its impressive track record for MBC patients

Novel ADC-ICI combination therapy

Expanding use of T-DxD in HER2low and HER2 ultra-low MBC patients

HER2+ mBC 1stL T-Dxd

Sacituzumab tirumotecan - a new powerful ADC for advanced TNBC

The ADC revolution continues - ctDNA takes the next step in tumor characterization

First-line inavolisib/placebo + palbociclib + fulvestrant preferred in patients with PIK3CA HR+ HER2- advanced breast cancer

Chemo-free regimen in HER2+ luminal breast cancer

INAVO120 - updated results

CDK4/6i effective in premenopausal patients as well

Treatment beyond progression for CDK 4/6i

Endocrine therapy with Palbociclib + Trastuzumab

Already more in the 1stL?

CDK4/6 rechallenge

Chemo-free, CDK4/6 inhibitor-based combination active in HR+/HER2+ PAM50-luminal advanced breast cancer

Importante beneficio en la supervivencia global con TDxD en el CMm HER2+

La révolution de l'ADC se poursuit / ctDNA franchit une nouvelle étape dans la caractérisation des tumeurs

C'è ancora posto per la terapia endocrina nel BC HER2+?

Le traitement endocrinien a-t-il encore sa place dans la CB HER2+ ?

Leczenie bez chemioterapii, oparte na inhibitorze CDK4/6 aktywne w zaawansowanych rakach HR+/HER2+ o fenotypie luminalnym wg PAM50

Espansione dell'uso di T-DxD nelle pazienti con carcinoma mammario metastatico HER2-low e HER2 ultra-low

Regime senza chemioterapia nel carcinoma mammario luminoso HER2+

Disminución de la toxicidad relacionada con la OS con G-CSF y loperamide profiláctica

INAVO120: risultati aggiornati

Sacituzumab tirumotecan – nowy aktywny koniugat w leczeniu zaawansowanego raka trójujemnego

CDK4/6 rechallenge

Is the metformin story over? How to treat HFNS symptomatology?

PSMA-PET CT: Ready for clinical practice or a PROMISE for the future?

Interesting data - but not practice changing

Focus on Quality of Life

Deciphering EMBARK: Exploring Enzalutamide's Impact on Prostate Cancer Progression and Quality of Life

Radionukleotides - the next step forward

EMBARK: Quality of Life

Unlocking Insights: The ALLIANCE Trial redefining Prognostic Models in Metastatic Prostate Cancer

RCT in mCRPC

mCRCP CYCLONE 2 study

Unveiling the Potential: PSMA-PET in Prostate Cancer Staging - Insights from the PROMISE TRIAL

The evolving role of PSMA-PET with new agents

EMBARK demonstrates the importance of HRQoL benefit in both combination and monotherapy arms

ARASENS Post hoc analysis: Therapy after progression

Exploring the CHAARTED TRIAL: Optimizing Treatment Strategies in Metastatic Prostate Cancer

Important QoL data

mCRPC: Who benefits from which measures?

EV-Pembro shows consistent outcome - caution with subset analyses

Perioperative treamtent in MIBC - new data for the use of sacituzumab govitecan

What to do with Cis Gem Nivo?

Preoperative use of sacituzumab govitecan

Effect of an immune diet on the outcome after radical cystectomy

ASCO 2024: Time for the rare GU tumors?

Quality of life not affected by i. v. Pembro

Biomarkers and long-term outcomes in pts with low tumor burden

Modified FOLFIRINOX therapy as a good option for urachus carcinoma

MI-UC - News from EVP standard

Treatment of urachal carcinoma

ctDNA as a biomarker in metastatic bladder cancer

The Role of Topoisomerase Inhibitors in the preoperative setting of MIBC: The story has just begun

ASCO24: Bladder cancer highlights

The future of sacituzumab govitecan

Interim analysis of the SURE-01/02 study

ASCO 2024: momento para los tumores GU poco frequentes?

ASCO24: Bladder cancer highlights

El papel de los inhibidores de topoisomerasa en el contexto perioperatorio del cancer de vejiga musculo infiltrante: la historia acaba de empezar

Biomarcadores y resultados a largo plazo en pacientes con baja carga tumoral

El futuro de sacituzumab govitecan

Supportive real-world data from German research platform CARAT

Evaluating risk criteria and monotherapy in mRCC

Advancing our understanding of biological mechanisms and the quest for the Ideal biomarker - Part 1

Advancing Our Understanding of Biological Mechanisms and the Quest for the Ideal Biomarker - Part 2

Combination is superior to monotherapy - how do we translate the results into clinical practice?

New HIF inhibitor in clear cell RCC

Treatment of favorable prognosis mRCC patients: additional data to support treatment decisions

Belzutifan in earlier lines in advanced ccRCC

DFF332 a novel HIF inhibitor

The search of the ideal biomarker in advanced renal cell carcinoma: The Sisyphus myth?

Adjuvant KIM-1 as prognostic & predictive biomarker

New IMDC risk group - very favorable

KIM-1 - old wine in new bottles

Metastasized chromophobe RCC

The never ending saga of biomarkers

KIM-1: Will have a major impact

Another breakthrough perioperative

Biomarker analysis of KN426 & CLEAR

NIVO+CABO: significantly longer therapy-free time

nccRCC

Combination therapies for chromophobe renal cell carcinoma are clearly superior

La busqueda del marcador ideal en el cancer renal avanzado: el mito de Sísifo?

Tratamiento del cancer renal avanzado de pronostico favorable: datos adicionales para ayudar en la decision clinica

Adjuvant therapy: how to identify patients who will benefit

End of the story in EGFRm disease?

4-year efficacy of Keynote-799 and ctDNA

Perioperative chemotherapy and N2 status

Early change in SOC in EGFR+ LD-NSCLC

Liquid biopsy in curative situation

ctDNA predicts outcome in patients treated with osimertinib

4y follow-up of CheckMate 816

Osimertinib improves PFS in stage III

CheckMate 816: 4-year update

Stadium III EGFR+: now permanently Osimertinib?!

Gamechanger in EGFR-mutated NSCLC

Confirmed efficacy of periop IO in N2 R-NSCLC

Cambio temprano en el tratamiento estándar del EGFR+ LD-NSCLC

4y follow-up de CheckMate 816

Le traitement adjuvant par osimertinib apres CTRT : changement de donne dans le cas du CBNPC muté EGFR

KRAS in NSCLC - a lot to come

Update for EGFR-positive NSCLC

Lorlatinib with extraordinary data in ALK + NSCLC

TROP2-targeting ADCs: where a we heading?

Subcut amivantamab - the future

Confirmed efficacy of adagrasib in KRASG12C

ALK+ NSCLC - CROWN revisited

KRASG12C - the story continues

Adagrasib for KRASG12C mutation 2nd line

EGFR+ NSCLC - amivantamab-based combination therapy

The end for local therapy for oligometastatic disease

KRAS building on single agent therapy

BAY297088 - Promising Her2-Inhibitor in NSCLC

ADCs - moving landscapes. Subgroups remain to be defined.

Telehealth is just as effective as a face-to-face visit in early palliative care

ASCO 2024 highlights

Confirmed efficacy in PD-L1 negativity - CheckMate 9LA

Lorlatinib convincing in ALK mutation 1st line

BAY297088 - Inhibiteur Her2-Inhibitor dans le NSCLC

La télésanté est aussi efficace qu'une consultation face a face dans les soins palliatifs précoces

KRASG12C - het verhaal gaat verder

ASCO 2024 highlights

ASCO 2024 highlights

Het einde van lokale therapie voor oligometastatische ziekte

Redefining SOC in LD-SCLC: Durvalumab as consolidation therapy

New SoC for LD-SCLC

Maintenance with durvalumab is the new SOC after chemo/radio therapy for LD-SCLC

LD-SCLC: What´s about PCI?

Tarlatamab shows activity in patients with brain metastasis

Finally, change for LS-SCLC

Le traitement d'entretien avec le durvalumab est le nouveau SOC après la chimio/radiothérapie pour le carcinomes à petites cellules en forme limitée

Tot slot, verandering voor LS-SCLC

Unexpected results; which subgroup could benefit from atezolizumab?

Harsh to beat

Chemo-immuno in mesothelioma - update

Difícil de superar

10 years follow up - immunotherapy for BRAF-mutated melanoma

Stimulating new combination of two antibody-cytokine fusions

Is the induction treatment the new strategy for selected patient group?

Personalized mRNA-vaccination: Practice changer of the future?

Is adjuvant treatment still standard in macroscopic, resectable stage III melanoma?

Is the triplet ready for phase 3?

Emerging rescue therapies for PD1 refractory melanoma

TIL therapy for metastatic melanoma

A new triplet for metastatic melanoma

No differences in PFS between the two study arms

Identifying patients with longterm benefits during tebentafusp in mUM

Promising activity of brenetafusp in PD-L1 refractory melanoma

Longterm survival after adjuvant targeted therapy

Impactful studies from ASCO 24 II: Combi-AD

Promising Results: Triple combination therapy in advanced melanoma

Neoadjuvant immunotherapy treatment for melanoma

Triple checkpoint blockade - a new approach?

Survival data for TT with dabrafenib and trametinib

Impactful studies from ASCO 24 III: Cell-therapy

Intralesional therapy with Daromun

Neoadjuvant intratumoral therapy with Daromun in metastatic melanoma

3-year update on mRNA vaccines in melanoma

Vaccine in combination with nivolumab for PDL1 resistance

Impactful studies from ASCO 24 I: NADINA

Adjuvant therapy with dabrafenib and trametinib - final results after 4 years

New oncolytic immunotherapy (RP1) after PD-1 failure

Lentigo maligna therapy

Consolidation of the use of IO in clinically detectable stage III melanoma

Progress in neoadjuvant therapy with IO

mRNA vaccine plus pembrolizumab in adjuvant therapy

A new therapy benchmark for brain-met melanoma patients

No hubo diferencias en la PFS entre los dos brazos del estudio

Prometedora actividad de brenetafusp en melanoma refractario a PD-L1

Consolidación del uso de IO en melanoma en estadio III clínicamente detectable

Risultati promettenti: Tripla terapia di combinazione nel melanoma avanzato

Encouraging developmental IO-options

New therapeutic approaches: Get over PD1 resistances?

New insights in localized HNSCC

New MOA in r/m HNSCC

New perspectives in HPV+ r/m HNSCC

Clear cell carcinomas benefit from IO therapy

New idea: anti-digest for EC?

De-escalation in ovarian cancer?